- Joint Appointment in Biomedical Engineering
- Joint Appointment in Oncology
- Joint Appointment in Ophthalmology
Jamie Berta Spangler, Ph.D.
Prof. Spangler’s research aims to expand the repertoire of protein therapeutics by redesigning naturally occurring proteins and engineering new molecules to overcome the deficiencies of existing drugs. Integrating cutting-edge tools from structural biophysics, biomolecular engineering, and translational immunology, her research focuses on developing innovative platforms for the discovery and design of proteins that recruit novel mechanisms for disease therapy. In particular, Spangler’s group is interested in engineering antibody-based molecules that reshape immune cell behavior for targeted treatment of cancer, infectious diseases, and autoimmune disorders. The overarching goal of her interdisciplinary research program is to establish new insights into protein behavior and the extent to which it can be manipulated for medically relevant applications.
Lab Website: Spangler Lab
J.B. Spangler, J. Tomala, V.C. Luca, K.M. Jude, S. Dong, A.M. Ring, P. Votavova, M. Pepper, M. Kovar, K.C. Garcia. “Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms.” Immunity, 42(5):815-825, May 2015.
J.B. Spangler, I. Moraga, J.L. Mendoza, K.C. Garcia. “Insights into cytokine-receptor interactions from cytokine engineering.” Annu Rev Immunol, 33:139-167, 2015.
J.B. Spangler, M.T. Manzari, E.K. Rosalia, T. F. Chen, K.D. Wittrup. “Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.” J Mol Biol, 422(4):532-544, Sep 2012.
J.B. Spangler, J.R. Neil, S. Abramovitch, Y. Yarden, F. M. White, D. A. Lauffenburger, K.D. Wittrup. “Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.” Proc Natl Acad Sci U S A, 107(30):13252-13257, Jul 2010.